OBJECTIVE: Enzymatic degradation of the extracellular matrix is known to be powerful regulator of atherosclerosis. However, little is known about the enzymatic regulation of heparan sulfate proteoglycans (HSPGs) during the formation and progression of atherosclerotic plaques. METHODS AND RESULTS: Swine were rendered diabetic through streptozotocin injection and hyperlipidemic through a high fat diet. Arterial remodeling and local endothelial shear stress (ESS) were assessed using intravascular ultrasound, coronary angiography and computational fluid dynamics at weeks 23 and 30. Coronary arteries were harvested and 142 arterial subsegments were analyzed using histomorphologic staining, immunostaining and real time PCR. Heparanase staining and activity was increased in arterial segments with low ESS, in lesions with thin cap fibroatheroma (TCFA) morphology and in lesions with severely degraded internal elastic laminae. In addition, heparanase staining co-localized with staining for CD45 and MMP-2 within atherosclerotic plaques. Dual staining with gelatinase zymography and heparanase immunohistochemical staining demonstrated co-localization of matrix metalloprotease activity with heparanase staining. A heparanase enzymatic activity assay demonstrated increased activity in TCFA lesions, subsegments with low ESS and in macrophages treated with oxidized LDL or angiotensin II. CONCLUSIONS: Taken together, our results support a critical role for heparanase in the development of vulnerable plaques and suggest a novel therapeutic target for the treatment of atherosclerosis.
OBJECTIVE: Enzymatic degradation of the extracellular matrix is known to be powerful regulator of atherosclerosis. However, little is known about the enzymatic regulation of heparan sulfate proteoglycans (HSPGs) during the formation and progression of atherosclerotic plaques. METHODS AND RESULTS:Swine were rendered diabetic through streptozotocin injection and hyperlipidemic through a high fat diet. Arterial remodeling and local endothelial shear stress (ESS) were assessed using intravascular ultrasound, coronary angiography and computational fluid dynamics at weeks 23 and 30. Coronary arteries were harvested and 142 arterial subsegments were analyzed using histomorphologic staining, immunostaining and real time PCR. Heparanase staining and activity was increased in arterial segments with low ESS, in lesions with thin cap fibroatheroma (TCFA) morphology and in lesions with severely degraded internal elastic laminae. In addition, heparanase staining co-localized with staining for CD45 and MMP-2 within atherosclerotic plaques. Dual staining with gelatinase zymography and heparanase immunohistochemical staining demonstrated co-localization of matrix metalloprotease activity with heparanase staining. A heparanase enzymatic activity assay demonstrated increased activity in TCFA lesions, subsegments with low ESS and in macrophages treated with oxidized LDL or angiotensin II. CONCLUSIONS: Taken together, our results support a critical role for heparanase in the development of vulnerable plaques and suggest a novel therapeutic target for the treatment of atherosclerosis.
Authors: A M Henney; P R Wakeley; M J Davies; K Foster; R Hembry; G Murphy; S Humphries Journal: Proc Natl Acad Sci U S A Date: 1991-09-15 Impact factor: 11.205
Authors: Peter H Stone; Ahmet Umit Coskun; Yerem Yeghiazarians; Scott Kinlay; Jeffrey J Popma; Richard E Kuntz; Charles L Feldman Journal: Curr Opin Cardiol Date: 2003-11 Impact factor: 2.161
Authors: Morteza Naghavi; Peter Libby; Erling Falk; S Ward Casscells; Silvio Litovsky; John Rumberger; Juan Jose Badimon; Christodoulos Stefanadis; Pedro Moreno; Gerard Pasterkamp; Zahi Fayad; Peter H Stone; Sergio Waxman; Paolo Raggi; Mohammad Madjid; Alireza Zarrabi; Allen Burke; Chun Yuan; Peter J Fitzgerald; David S Siscovick; Chris L de Korte; Masanori Aikawa; K E Juhani Airaksinen; Gerd Assmann; Christoph R Becker; James H Chesebro; Andrew Farb; Zorina S Galis; Chris Jackson; Ik-Kyung Jang; Wolfgang Koenig; Robert A Lodder; Keith March; Jasenka Demirovic; Mohamad Navab; Silvia G Priori; Mark D Rekhter; Raymond Bahr; Scott M Grundy; Roxana Mehran; Antonio Colombo; Eric Boerwinkle; Christie Ballantyne; William Insull; Robert S Schwartz; Robert Vogel; Patrick W Serruys; Goran K Hansson; David P Faxon; Sanjay Kaul; Helmut Drexler; Philip Greenland; James E Muller; Renu Virmani; Paul M Ridker; Douglas P Zipes; Prediman K Shah; James T Willerson Journal: Circulation Date: 2003-10-14 Impact factor: 29.690
Authors: Anthony J Monteforte; Brian Lam; Subhamoy Das; Somshuvra Mukhopadhyay; Catherine S Wright; Patricia E Martin; Andrew K Dunn; Aaron B Baker Journal: Biomaterials Date: 2016-04-11 Impact factor: 12.479
Authors: Ahmet Seyfeddin Gurbuz; Semi Ozturk; Suleyman Cagan Efe; Mehmet Fatih Yilmaz; Raziye Ecem Yanik; Ali Yaman; Cevat Kirma Journal: Med Princ Pract Date: 2019-09-04 Impact factor: 1.927
Authors: G Rao; H G Ding; W Huang; D Le; J B Maxhimer; A Oosterhof; T van Kuppevelt; H Lum; E J Lewis; V Reddy; R A Prinz; X Xu Journal: Diabetologia Date: 2011-03-20 Impact factor: 10.122
Authors: Peter L Voyvodic; Daniel Min; Robert Liu; Evan Williams; Vipul Chitalia; Andrew K Dunn; Aaron B Baker Journal: J Biol Chem Date: 2014-02-19 Impact factor: 5.157